The U.S. Supreme Court rejected Maryland’s bid to revive a law aimed at preventing price gouging by pharmaceutical companies, dealing a setback to the power of states to rein in prescription drug costs.
More than 100 Boston-area employees from two pharma companies are getting pink slips. Roche and Forma Therapeutics filed WARN notices with the state of Massachusetts.
London-based Autolus Therapeutics announced plans to locate the company’s U.S. headquarters in Rockville, Maryland.
Members of the wealthy Sackler family behind Purdue Pharma LP pushed the company to boost sales of OxyContin and other opioids even as questions emerged about the extent the drugmaker’s painkillers were being abused, Massachusetts’ attorney general alleged.
AstraZeneca filed a Worker Readjustment and Retraining Notification Act (WARN) notice with the State of Colorado, indicating plans to lay off 210 people in Boulder and Longmont.
A judge dismissed lawsuits filed by 37 different municipal governments pertaining to opioid drugmakers being sued in the state of Connecticut.
Akorn Inc. received a warning letter from the U.S. Food and Drug Administration following an inspection of the generic drugmaker’s Decatur, Illinois manufacturing plant during 2018.
New York City launched a $100 million health insurance program to cover 600,000 uninsured residents, including those unable to afford coverage and those living in the United States illegally.
Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world’s top-selling medicine Humira, although the pace of price hikes was slower than during 2018.